Skip to main content
 

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
12/11/17Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND
Lead candidate targets C9ORF72; in vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced data from preclinical studies of WVE-3972-01, the company’s investigational stereopure antisense oligonu... 
Printer Friendly Version
11/09/17Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the third quarter ended September 30, 2017. “Through the growth of talent and capabilities in our organization and excellent execution throughout the quarter, we achieved our ambitious c... 
Printer Friendly Version
11/06/17Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne Muscular Dystrophy (DMD)
First clinical trial of WVE-210201, an exon 51 skipping investigational therapy, in ambulatory and non-ambulatory boys 5 to 18 years old CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the initiation of a global Phase 1 clinical trial for WVE-210201 in Duchenn... 
Printer Friendly Version
10/26/17Wave Life Sciences Unveils New Manufacturing Facility in Lexington, MA
90,000 Square Foot Facility to Support Company's Advancement of Stereopure Nucleic Acid Platform; Furthers Commitment to Patient Communities CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the public opening of its new 90,000 square foot state-of-the-art manu... 
Printer Friendly Version
10/12/17Wave Life Sciences to Present at the Jefferies Gene Technology Investor Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 12, 2017-- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies Gene Technology Investor Summit on Thursday, October 12, 2017 at 8:20 A.M. ET in New York, New York. A live web... 
Printer Friendly Version
08/22/17Wave Life Sciences Announces Publication of Paper in Nature Biotechnology Establishing the Importance of Stereochemical Purity in Oligonucleotide Drug Design
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 22, 2017-- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the publication of a new paper in the September issue of Nature Biotechnology. The paper describes a breakthrough method to produce antisense oligonucleotide (ASO) therapeutics with high stereochemical purity as well... 
Printer Friendly Version
08/09/17Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the second quarter ended June 30, 2017. “We recently achieved two major milestones: transitioning to a clinical stage company, with the commencement of our two phase 1b/2a trials in Hunt... 
Printer Friendly Version
07/17/17Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease
Trials Evaluate the First Allele-Specific Investigational Drugs for Huntington’s Disease, WVE-120101 and WVE-120102 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 17, 2017-- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the initiation of the Company’s PRECISION-HD program, which includes PRECISION-HD1 and ... 
Printer Friendly Version
06/08/17ReadCoor and WAVE Life Sciences Initiate Research Collaboration
Collaboration aims to unlock next generation stereopure nucleic acid targets with novel FISSEQ technologies CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2017-- ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, and WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the initia... 
Printer Friendly Version
06/06/17WAVE Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be participating at the following upcoming investor conferences: Jefferies 2017 Global Healthcare Conference – WAVE Company Presentation Wednesday, ... 
Printer Friendly Version
05/10/17WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced financial results for the first quarter ended March 31, 2017. “The beginning of 2017 was marked by continued advancement of our lead programs in HD and DMD and substantial progress in our collaboration with Pfizer. Our two HD pro... 
Printer Friendly Version
04/12/17WAVE Life Sciences Prices Public Offering of 4,166,667 Ordinary Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 12, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, announced today the pricing of its previously announced underwritten public offering of 4,166,667 of its ordinary shares at a price to the public of $24.00 per ordinary share. Net proceeds to WAVE Life Sciences from the offering are expected to be approximate... 
Printer Friendly Version
04/11/17WAVE Life Sciences Announces Proposed Public Offering of Ordinary Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 11, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, announced today that it has commenced an underwritten public offering of its ordinary shares. In connection with the offering, WAVE intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in ... 
Printer Friendly Version
03/16/17WAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update
On track to take first three lead programs into the clinic in 2017 Clinical trials expected to commence in Huntington’s disease mid-2017, Duchenne Muscular Dystrophy second half of 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today reported financial results for the fourth quarter and ... 
Printer Friendly Version
02/06/17WAVE Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences: Leerink Partners Global Healthcare Conference 2017 Wednesday, February 15th at 1:30... 
Printer Friendly Version
01/06/17WAVE Life Sciences 2017 Pipeline Update
Three Lead Neurology Programs to Enter Clinic in 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced updates to its clinical pipeline for 2017. “2017 will be an important year for WAVE as we transition our two lead candidates in Huntington’s disease and our exon-skipping candida... 
Printer Friendly Version